Peppermint and Digestive Comfort: What 16 Clinical Trials Can—and Cannot—Tell Us

A 2025 systematic review brought together 16 human clinical trials involving Mentha preparations and gastrointestinal conditions. That number makes an appealing headline—but the details determine what the research can actually support.

The most important detail is simple: the clinical literature was mainly about peppermint oil, not ordinary peppermint leaf powder.

What the review examined

The authors searched MEDLINE/PubMed, Cochrane, and EMBASE and used PRISMA methods to select human intervention studies. The 16 included trials covered several populations:

• nine trials involving irritable bowel syndrome;
• three involving functional dyspepsia;
• two involving healthy volunteers;
• one involving pediatric functional abdominal pain; and
• one involving people with upper or lower digestive complaints.

Most interventions used peppermint oil. Some tested peppermint oil with caraway oil or other multi-ingredient preparations. This variation makes it inappropriate to treat all 16 studies as though they tested one uniform peppermint product.

What the peppermint-oil trials reported

Several studies reported improvements in measures such as abdominal discomfort, pain, distension, or overall symptom scores. In the trials involving irritable bowel syndrome, the review described commonly studied regimens as enteric-coated capsules containing approximately 182 to 225 mg of peppermint oil, used more than once daily over roughly two to eight weeks.

Not every study was positive. Two trials did not find peppermint oil superior to the comparison for most outcomes. The review's authors concluded that more trials are needed to clarify effectiveness, formulation, dose, and safety.

What the review does not prove

The review does not prove that every peppermint product will produce the outcomes seen in a particular trial. It does not establish that peppermint leaf powder is equivalent to concentrated peppermint oil. It also does not prove that a lower dose, a different delivery system, or a combination formula will behave like an enteric-coated oil capsule.

Those are not minor technicalities. Botanical research is preparation-specific:

• Identity matters: peppermint leaf, extract, and essential oil have different constituent profiles.
• Dose matters: milligrams of plant powder are not equivalent to milligrams of essential oil.
• Delivery matters: an enteric coating changes where a capsule is intended to release.
• Population matters: findings in diagnosed study participants do not automatically predict results in every consumer.
• Combination matters: a peppermint-and-caraway product cannot establish the effect of peppermint alone.

How the earlier peppermint review fits

McKay and Blumberg's 2006 review helps explain the distinction. It described peppermint leaf as a source of phenolic constituents including rosmarinic acid and flavonoids, while the essential oil was characterized mainly by volatile compounds such as menthol and menthone. The review found that human research had concentrated on peppermint oil; human evidence for peppermint leaf was limited.

The 2025 paper expands the clinical overview, but the same central lesson remains: the strongest gastrointestinal trial evidence belongs to specific peppermint-oil formulations.

A consumer-friendly reading of the evidence

There is a legitimate scientific basis for continued interest in peppermint and digestive comfort. There is also a legitimate reason to be precise. A responsible brand can discuss the research without turning a botanical ingredient into a disease-treatment promise.

For shoppers, the best questions are: What exact peppermint preparation is in this product? How much is present? Does the label explain the form? Does the marketing stay within what that formulation can honestly support?

What this means for Enterophyne

Enterophyne provides 75 mg of Mentha piperita powder per serving in a formula paired with turmeric. It is designed as a botanical option for daily digestive support and digestive comfort.

Because Enterophyne uses peppermint powder rather than an enteric-coated peppermint-oil formulation, the clinical-trial outcomes summarized in the 2025 review should not be presented as direct evidence that Enterophyne treats a gastrointestinal disorder. The connection is ingredient relevance and informed formulation—not clinical equivalence.

To understand the ingredient forms, read Mentha piperita Explained. To compare capsule types, see Peppermint Capsules vs. Peppermint Oil Capsules.

Safety perspective

The National Center for Complementary and Integrative Health reports that oral peppermint oil can cause heartburn, nausea, abdominal pain, or dry mouth, and that the long-term safety of consuming large amounts of peppermint leaf is not known. Talk with a health professional before using an herbal supplement if you take medication, are pregnant or breastfeeding, have reflux, or have persistent digestive symptoms.

The 2006 review also reported preliminary human findings involving non-heme iron absorption and the prescription drug felodipine. Those results concerned particular peppermint preparations and should not be generalized to every product, but they are another reason to review botanical supplements with a clinician when medications or nutrient deficiencies are involved.

Sources

• Investigating the Health Potential of Mentha Species Against Gastrointestinal Disorders—A Systematic Review of Clinical Evidence. Pharmaceuticals. 2025.
• McKay DL, Blumberg JB. A review of the bioactivity and potential health benefits of peppermint tea (Mentha piperita L.). Phytotherapy Research. 2006.
• NCCIH: Peppermint Oil—Usefulness and Safety.

This article is for educational purposes and is not medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent disease. Seek medical care for persistent, severe, or unexplained symptoms.